Literature DB >> 20483621

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.

Karen L Milkiewicz1, Linda R Weinberg, Mark S Albom, Thelma S Angeles, Mangeng Cheng, Arup K Ghose, Renee C Roemmele, Jay P Theroff, Ted L Underiner, Craig A Zificsak, Bruce D Dorsey.   

Abstract

Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a variety of cancers. A series of tetrahydropyrido[2,3-b]pyrazines was constructed as ring-constrained analogs of a known aminopyridine kinase scaffold. Chemistry was developed to rapidly elaborate the SAR, structural elements impacting ALK inhibitory activity were exploited, and kinase selective analogs were identified that inhibit ALK with IC(50) values approximately 10 nM (enzyme) and approximately 150 nM (cell). Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483621     DOI: 10.1016/j.bmc.2010.04.087

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.

Authors:  Gregory R Ott; Rabindranath Tripathy; Mangeng Cheng; Robert McHugh; Andrew V Anzalone; Ted L Underiner; Matthew A Curry; Matthew R Quail; Lihui Lu; Weihua Wan; Thelma S Angeles; Mark S Albom; Lisa D Aimone; Mark A Ator; Bruce A Ruggeri; Bruce D Dorsey
Journal:  ACS Med Chem Lett       Date:  2010-09-01       Impact factor: 4.345

Review 2.  ALK and ROS1 as a joint target for the treatment of lung cancer: a review.

Authors:  Raimon Puig de la Bellacasa; Niki Karachaliou; Roger Estrada-Tejedor; Jordi Teixidó; Carlota Costa; José I Borrell
Journal:  Transl Lung Cancer Res       Date:  2013-04

Review 3.  Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.

Authors:  Muhammad Latif; Zaman Ashraf; Sulman Basit; Abdul Ghaffar; Muhammad Sohail Zafar; Aamer Saeed; Sultan Ayoub Meo
Journal:  RSC Adv       Date:  2018-05-04       Impact factor: 4.036

Review 4.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

5.  Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.

Authors:  Jianyong Chen; Yunlong Zhou; Xuyuan Dong; Liu Liu; Longchuan Bai; Donna McEachern; Sally Przybranowski; Chao-Yie Yang; Jeanne Stuckey; Xiaoqin Li; Bo Wen; Ting Zhao; Siwei Sun; Duxin Sun; Lingling Jiao; Yu Jing; Ming Guo; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2020-11-13       Impact factor: 7.446

6.  ALK and NSCLC: Targeted therapy with ALK inhibitors.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  F1000 Med Rep       Date:  2011-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.